2 completed, 1 active not recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow H3B-6545: new trials by email Literature Review of H3B-6545 trials Research Report on H3B-6545
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer H3B-6545, Antihistamine - Breast Neoplasms | Phase 1 | Completed | Eisai Co., Ltd. | 33 | 2020-09-30 | 2025-10-23 |
| A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg) - Receptors, Estrogen, Genes, Erbb-2 | Phase 1 | Active not recruiting | Eisai Inc. | 31 | 2020-04-01 | 2026-08-27 |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer H3B-6545 - Breast Neoplasms, Breast Cancer | Phase 1 / Phase 2 | Completed | Eisai Inc. | 151 | 2017-08-23 | 2025-02-25 |
Breast Neoplasms (3)
Eisai Inc. (2) · Eisai Co., Ltd. (1)
United Kingdom (2) · United States (2) · France (1) · Japan (1)
2018 (1), 2019 (1)